54 - Monoclonal antibodies approved for Hematological and Solid tumors

ANTIGEN AND TUMOR CELL TARGETS	ANTIGEN FUNCTION	NAKED ANTIBODIES
Antigen: CD20	Proliferation/differentiation	Rituximab (chimeric)
Tumor type: B-cell lymphoma and CLL
Antigen: CD52	Unknown	Alemtuzumab (humanized)
Tumor type: B-cell CLL and T-cell lymphoma
Antigen: CD25 alpha subunit	Activation antigen	Daclizumab (humanized)
Tumor type: T-cell mycosis fungoides
Antigen: CD33	Unknown	Gemtuzumab (humanized)
Tumor type: acute myeloid leukemia
Antigen: HER2/neu (ErbB-2)	Tyrosine kinase	Trastuzumab (humanized)
Tumor type: breast cancer
Antigen: EGFR (ErbB-1)	Tyrosine kinase	Cetuximab (chimeric)
Tumor type: colorectal; NSCLC; pancreatic, breast
Antigen: VEGF	Angiogenesis	Bevacizumab (humanized)
Tumor type: colorectal cancer

53 - Benzodiazepine interactions with other drugs

Benzodiazepine interactions with other drugs.

Drug Effects Antacids Decreased absorption of benzodiazepines Cimetidine Increased half-life of diazepam and  triazolam Contraceptives Increased levels of diazepam and  triazolam Digoxin Alprazolam and diazepam raise  digoxin level Disulfiram Increased duration of action of sedatives Isoniazid Increased plasma diazepam Levodopa Inhibition of antiparkinsonism effect Propoxyphene Impaired clearance of diazepam Rifampin Decreased plasma diazepam Warfarin Decreased prothrombin time